Surgical Innovations Group said its trading performance for the current financial year to date is in line with directors' expectations.
"Revenues show strong growth compared with the corresponding period in the prior year, with gross margins delivered within the target range," said executive chair Nigel Rogers in a statement.
"Product innovation continues to be a priority, with focus on the further development of the YelloPort Elite range, our next generation Resposable port access system and the launch of further products to enhance our ranges of retraction and ligation solutions.
"The overall level of expenditure on product development has been maintained at a similar proportion of revenue as last year, demonstrating our ongoing commitment to innovation.
"The Group continues to be cash generative, with net cash resources building whilst maintaining investment in development, and a modest increase in working capital due to the increased activity level. Overall, the Board is satisfied with progress."